All the reviewed papers assessed variable PSMA-targeting radiopharmaceuticals uptake in primary and metastatic ccRCC lesions; most reports reported it was higher than the activity of the surrounding tissue. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.